Physician profile
Mark A Twardowski
NPI 1437118387
$1,334.28
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $302 · 2021: $40.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $203.71 | 2019-2020 | |
| Novo Nordisk INC | $179.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.32 | 2019-2020 | |
| Pfizer INC. | $124.49 | 2019-2020 | |
| Amgen INC. | $100.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $91.64 | 2019-2020 | |
| Allergan, INC. | $90.60 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $78.08 | 2019-2021 | |
| Medtronic Minimed, INC. | $74.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $71.53 | 2019 | |
| Glaxosmithkline, LLC. | $58.63 | 2019 | |
| Sanofi Pasteur INC. | $52.69 | 2019-2020 | |
| Abbvie INC. | $43.16 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $13.72 | 2019 | |
| Merck Sharp & Dohme LLC | $10.98 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Twardowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.